Featured Platforms

Custom Protein Generation

Mammalian- Derived Products

Microbial- Derived Products

Antibody Drug Conjugates

Bispecific Ab Platform

Technologies & Platforms

Dear valued partners and clients,

As the COVID-19/coronavirus outbreak becomes a global pandemic, please know that our thoughts are with you.  We hope you, your family and your colleagues are safe and can avoid the virus. At WuXi Biologics, we suffered the virus outbreak about two months ago and the resulting challenges are now subsiding (see WuXi Biologics Business Continuity and Impact Statement here). More than 97% of our dedicated employees are back at work. All global shipments of materials and products have returned to a business-as-usual status.  In the city of Wuxi, which has approximately 8 million people, a total of 55 people were infected and no fatalities were reported as a result of the outbreak. Over the past 22 days, there have been no new infections reported. So our business is truly back to normal.

Having contended with the virus for almost 45 days, we gained a lot of first-hand experience that we would like to share with you (click here for more information). We hope you will find this information useful. If you are interested in learning more about our practices, please contact us at info@wuxibiologics.com and reference “COVID-19 WuXi Biologics best practice.”

In ancient Chinese wisdom, whenever there is a crisis, great opportunities also emerge. We hope that all of us will win the battle against the coronavirus and come back even stronger!

If you have a mission-critical project with a timeline potentially impacted by the coronavirus, we are here to help. If your CDMO partner or your internal team need to stay at home, we can help keep your important projects moving forward and expedite your programs so they stay on their original timelines.  Please do not hesitate to contact us at info@wuxibiologics.com if there is any way we can help support your efforts to bring critical medicines into the clinic and beyond.

All the best,

Chris Chen, Ph.D.
Chief Executive Officer
WuXi Biologics